**Hepatitis B Country Profile**

**Country Demographics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Population (2018)</td>
<td>4,818,977</td>
</tr>
<tr>
<td>Urban Population (% of total, 2018)</td>
<td>51.2%</td>
</tr>
<tr>
<td>Health expenditure per capita ($US, 2016)</td>
<td>$68.3</td>
</tr>
<tr>
<td>Health expenditure, total (% of GDP, 2016)</td>
<td>9.6%</td>
</tr>
<tr>
<td>Total births (2013)</td>
<td>152,000</td>
</tr>
<tr>
<td>Surviving Infants (2013)</td>
<td>143,000</td>
</tr>
<tr>
<td>Life expectancy at birth (years, 2017)</td>
<td>63 years</td>
</tr>
<tr>
<td>Number of districts (2013)</td>
<td>15</td>
</tr>
</tbody>
</table>

**HBsAg Prevalence**

<table>
<thead>
<tr>
<th>Year</th>
<th>Pre-vaccine HBsAG+ (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2000</td>
<td>17.2%</td>
</tr>
</tbody>
</table>

**Liver Cancer as Cause of Cancer Death (in Men)**

<table>
<thead>
<tr>
<th>Year</th>
<th>Ranking</th>
<th>Country Comparison in African Region (47 Countries)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2018</td>
<td>2</td>
<td>Liberia: HepB3</td>
</tr>
</tbody>
</table>

**2018 Country Comparison in African Region (47 Countries)**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Liberia</th>
<th>Number of countries with reported coverage</th>
<th>Highest reported coverage in AFR</th>
<th>Lowest reported coverage in AFR</th>
</tr>
</thead>
<tbody>
<tr>
<td>HBsAg Prevalence3</td>
<td>17.2%</td>
<td>47</td>
<td>99% (Cabo Verde, Seychelles)</td>
<td>25% (Equatorial Guinea)</td>
</tr>
<tr>
<td>HepB3</td>
<td>84%</td>
<td>4</td>
<td>99% (Algeria)</td>
<td>63% (Senegal)</td>
</tr>
<tr>
<td>HepB BD4</td>
<td>NR</td>
<td>4</td>
<td>99% (Algeria)</td>
<td>63% (Senegal)</td>
</tr>
</tbody>
</table>

**Hepatitis B Immunization Coverage**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>HepB3</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>64%</td>
<td>64%</td>
<td>47%</td>
<td>77%</td>
<td>80%</td>
<td>76%</td>
<td>50%</td>
<td>52%</td>
<td>79%</td>
<td>86%</td>
<td>84%</td>
</tr>
<tr>
<td>HepB BD</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td>BCG</td>
<td>78%</td>
<td>73%</td>
<td>69%</td>
<td>64%</td>
<td>60%</td>
<td>76%</td>
<td>77%</td>
<td>77%</td>
<td>85%</td>
<td>87%</td>
<td>73%</td>
<td>85%</td>
<td>85%</td>
<td>87%</td>
<td>73%</td>
<td>74%</td>
<td>97%</td>
<td>87%</td>
<td>92%</td>
</tr>
</tbody>
</table>

**Liver Cancer as Cause of Cancer Death (in Men)**

<table>
<thead>
<tr>
<th>Year</th>
<th>Ranking</th>
<th>Country Comparison in African Region (47 Countries)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2018</td>
<td>2</td>
<td>Liberia: HepB3</td>
</tr>
</tbody>
</table>

**Hepatitis B Immunization Coverage**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>HepB3</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>64%</td>
<td>64%</td>
<td>47%</td>
<td>77%</td>
<td>80%</td>
<td>76%</td>
<td>50%</td>
<td>52%</td>
<td>79%</td>
<td>86%</td>
<td>84%</td>
</tr>
<tr>
<td>HepB BD</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td>BCG</td>
<td>78%</td>
<td>73%</td>
<td>69%</td>
<td>64%</td>
<td>60%</td>
<td>76%</td>
<td>77%</td>
<td>77%</td>
<td>85%</td>
<td>87%</td>
<td>73%</td>
<td>85%</td>
<td>85%</td>
<td>87%</td>
<td>73%</td>
<td>74%</td>
<td>97%</td>
<td>87%</td>
<td>92%</td>
</tr>
</tbody>
</table>

**Liberia: HepB3**

- **Coverage Rate (%)**
  - Year 2000: 64%
  - Year 2002: 64%
  - Year 2004: 47%
  - Year 2006: 80%
  - Year 2008: 76%
  - Year 2010: 50%
  - Year 2012: 52%
  - Year 2014: 79%
  - Year 2016: 86%
  - Year 2018: 84%

**Abbreviations:**